ClinicalTrials.gg
CompletedNCT07348133Updated Feb 12, 2026

Study of Food Effect on Pharmacokinetics of HMPL-523 Acetate Tablets

A Phase 1 interventional study of HMPL-523 in Healthy, sponsored by Hutchmed. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Hutchmed · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a single-center, open-label, randomized, three-period, six-sequence study to evaluate the effect of food (high-fat and low-fat) on the PK of HMPL-523. In this study, 18 healthy Chinese participants are planned to be enrolled, randomized in a ratio of 1:1:1:1:1:1 to one of 6 dosing sequences (see dosing sequence table for details), and administered once per cycle for 3 cycles, with a washout period of at least 7 days. The study consists of a screening/baseline period, a dosing period (three cycles), and a follow-up period.

Read the detailed description

Screening Period/Baseline Period The trial participants will sign a written informed consent form on a voluntary basis prior to screening. Screening period/baseline period assessment will be completed within 14 days prior to the first dose. At screening/baseline, demographic data, medical history, medication history, allergy history, blood donation history, and participation in clinical trials should be collected, and physical examination, vital sign measurements, 12-lead ECG, infection markers, laboratory tests, pregnancy test , and chest X-ray will be performed.

Trial participants who pass the preliminary screening will be admitted to the study site 3 days prior to the first dose (i.e., 3 days prior to medication of Cycle 1), vital signs examination, urine drug abuse screening, alcohol breath screening will be performed on the day of admission, recent dietary and medication use will be inquired, and pregnancy test will be conducted (only for women of childbearing potential. If the screening examinations and baseline examinations will be conducted on the same day, they can be done once), and the inclusion and exclusion criteria will be further checked.

Only serious adverse events will be collected during screening/baseline period. Dosing Period (3 cycles) The day before the first administration, trial participants passing the screening will be given a randomization number according to the randomization scheme, and assigned to one of 6 dosing sequences in a ratio of 1:1:1:1:1:1. The dosing sequences include ABC, ACB, BAC, BCA, CAB and CBA, and the three dietary conditions are fasting (A), standard high-fat breakfast (B) and standard low-fat breakfast (C). Each participant will receive a single oral dose of HMPL-523 acetate tablets 300 mg (3 tablets × 100 mg) on Day 1 of each cycle in accordance with the dosing sequence. During the study, every effort should be made to ensure that the participant takes the medication according to the study protocol.

Administration Method Fasting (A): Participants will fast for at least 10 hours, have blank blood sample collected, and take the study drug with about 240 mL of water. Except for the water for drug administration mentioned above, water will be deprived from 1 hour pre-dose and 1 hour post-dose. Food will be deprived within 4 hours post-dose.

Standard high-fat breakfast (B) or standard low-fat breakfast (C): Participants will fast for at least 10 hours before the standard high-fat breakfast (B) or standard low-fat breakfast (C), start eating breakfast 30 minutes before dosing, and finish the meal within 25 minutes. After the meal, participants will have blank blood sample collected, and take the study drug with about 240 mL of water exactly 30 minutes from the start of the meal. Water will be deprived from 1 hour pre-dose to 1 hour post-dose, except for the beverages included in the prescribed breakfast and water taken with medication. Food will be deprived within 4 hours post-dose.

During hospitalization, the diet of the participants will be provided by the site. On the day of dosing in each cycle, lunch and dinner (both regular meals) will be served 4 hours and 10 hours after dosing, respectively; at other times, 3 meals will be provided according to the schedule arranged by the site.

The dosing period consists of three cycles, and the scheduled PK blood sampling time points for each participant in each cycle are as follows: within 0.5 hours pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, 24, 36, 48, 60,and 72 hours post-dose, with a total of 18 collections, and about 3 mL of venous blood will be collected each time. The 4-hour post-dose blood sample must be taken prior to lunch.

After the participants are admitted to the clinical study ward, the vital sign measurements will be performed 1 day pre-dose in each cycle and 3±1 hours post-dose on Day 1 of each cycle. Vital sign measurements, blood chemistry, and hematology will be performed on Day 4 of the each of Cycle 1 and Cycle 2. On Cycle 3 Day 4, the participants will be discharged after vital sign measurements, physical examination, laboratory tests, and 12-lead ECG examination are completed.

Strenuous exercise, alcohol, tobacco, tea, and caffeinated beverages should be avoided during the study. Seville oranges, grapefruits or beverages containing these fruits should be avoided during the study.

Follow-up Period Participants will be followed up to Day 12±2 after the last dose (the day of the last dose is defined as Day 1 of follow-up period). The investigator will collect all (adverse events) AEs and concomitant medications/therapies from the participants during this period through telephone calls (or other means such as text messages). If there are AEs ongoing at follow-up, follow-up will continue until the events return to normal level, abnormal and not clinically significant, baseline level, stable or lost to follow-up, or refusal to visit, etc.

02

Conditions studied

  • Healthy

Keywords

  • HMPL-523
03

In context

Lead sponsor

Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants can communicate well with the investigator, voluntarily sign the ICF, and agree to comply with the requirements of the study protocol;
  2. Male and female healthy participants aged 18-45 years (inclusive);
  3. Body weight ≥ 45 kg (females), or ≥ 50 kg (males), (BMI) 19-26 kg/m2 (inclusive);
  4. Participants must commit to using highly effective for both themselves and their sexual partners during the study, and for 180 days after the end of the last study dose, and must not engage in sperm donation, egg donation, or have birth plan.

Exclusion criteria

Exclusion Criteria:

  1. Abnormal and results of vital signs, physical examination, 12-lead , chest X-ray (frontal and lateral), laboratory tests (including hematology, blood chemistry, urinalysis, etc.) or serum creatinine above the at screening;
  2. Positive for any of the , antibody, antibody, or Treponema pallidum antibody;
  3. History or current evidence of severe or chronic metabolic/endocrine, hepatic, renal, hematological, pulmonary, immunological, cardiovascular, gastrointestinal, genitourinary, neurological or psychiatric diseases;
  4. Prior history of hypertension;
  5. Prior history of severe gastrointestinal diseases such as dysphagia, active gastric ulcers, etc., resulting in inability to take oral medication or disorders in absorption of oral medication
  6. Prior history of gastrointestinal surgery, renal surgery, cholecystectomy, etc. that, in the judgment of the investigator, may affect drug absorption or excretion;
  7. Prior history of drug allergy, or acute allergic rhinitis or food allergy within 2 weeks before screening, or allergy to the active ingredients or of the study drug;
  8. Use of any prescription drugs and Chinese herbal medicines within 30 days prior to the first dose;
  9. Use of any over-the-counter drugs, vitamins, and health products within 14 days prior to the first dose;
  10. Consumption of more than 10 cigarettes per day within 3 months before screening, or those who cannot quit smoking during the study;
  11. Regular alcohol consumption within 6 months before screening, that is, those who drink more than 14 units of alcohol per week (1 unit = 360 mL of beer, or 45 mL of spirits with an alcohol content of 40%, or 150 mL of wine), or those who cannot abstain from alcohol during the study, or those who are positive for alcohol breath test;
  12. History of drug abuse or recreational use, or positive for urine drug abuse screen;
  13. Blood donation (including blood component donation) or blood loss ≥ 400 mL within 3 months prior to screening, use of blood products within 2 months prior to screening, blood donation (including component blood donation) or lost blood ≥ 200 mL within 1 month prior to screening, or a plan to donate blood or blood components during the study or within 1 month after the end of the study;
  14. Difficulty in blood collection, or a history of needle phobia or blood phobia, or intolerance to blood sampling via venipuncture, or poor evaluation of venous blood collection;
  15. Those who have participated in clinical trials of other drugs/medical devices and have taken study drugs within 3 months prior to screening;
  16. Those who have consumed foods, juices or drinks containing alcohol, grapefruit, Seville oranges and caffeine within 72 hours before the first dose, or cannot avoid them during the study;
  17. Those who have received within 8 weeks prior to screening or have plans to be vaccinated during the clinical trial;
  18. Those who have special dietary requirements and cannot accept a standardized dietary arrangement;
  19. Pregnant or lactating females, or females with blood pregnancy test results above the upper limit of normal during the screening period, or females with unprotected sex within 2 weeks prior to dosing;
  20. The study participant, based on the judgment of the investigator, has any other diseases or conditions that may affect the normal completion of the study or the evaluation of study data, or other conditions that make him/her unsuitable for participation in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    ABC

    The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.

    Drug: HMPL-523

  • Experimental
    ACB

    The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.

    Drug: HMPL-523

  • Experimental
    BAC

    The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.

    Drug: HMPL-523

  • Experimental
    BCA

    The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.

    Drug: HMPL-523

  • Experimental
    CAB

    The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.

    Drug: HMPL-523

  • Experimental
    CBA

    The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.

    Drug: HMPL-523

Interventions

  • The 3 cycles of each sequence consist of 3 dietary conditions, i.e., fasting (A), standard high-fat breakfast (B), and standard low-fat breakfast (C). Participants will receive a single oral dose of HMPL-523 acetate tablets 300 mg on Day 1 of each cycle.

06

What researchers measure

Primary outcomes

  1. AUC0-t

    Area under the plasma concentration-time curve from time zero to the last time point t where the concentration could be accurately determined

    Time frame: up to one months

  2. AUC0-∞

    Area under the plasma concentration-time curve from time 0 to infinity

    Time frame: up to one months

  3. Cmax

    Maximum plasma concentration

    Time frame: up to one months

  4. Tmax

    Other PK parameters of HMPL-523, such as time to Cmax

    Time frame: up to one months

  5. t1/2

    Other PK parameters of HMPL-523, such as terminal elimination half-life

    Time frame: up to one months

Secondary outcomes

  1. Adverse events rate

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: up to one months

  2. Laboratory tests

    Number of participants with abnormal laboratory tests results

    Time frame: up to one months

07

Study locations

1 site
  • The First Affiliated Hospital of Shandong First Medical University
    Jinan, Shandong 250014, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Jan 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2025
First posted
Jan 16, 2026
StartActual
Dec 11, 2025
Primary completionActual
Jan 12, 2026
CompletionActual
Feb 6, 2026
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07348133
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Dec 11, 2025
Primary completion
Jan 12, 2026
Completion
Feb 6, 2026
Last update
Feb 12, 2026

Study contacts

Wei Zhao, Doctor
principal investigator · Shandong First Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sovleplenib

Start the discussion